Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 55Heterocyclic Compound Synthesis and BioactivityCancer therapeutics and mechanismsBioactive Compounds and Antitumor Agents

The DOI matches its Crossref record; 103 of the 104 references it cites were found in a registry or an index.

Repurposing of Benzimidazole Anthelmintic Drugs as Cancer Therapeutics

Open access

Abstract

Benzimidazoles have shown significant promise for repurposing as a cancer therapy. The aims of this review are to investigate the possibilities and limitations of the anti-cancer effects of benzimidazole anthelmintics and to suggest ways to overcome these limitations. This review included studies on the anti-cancer effects of 11 benzimidazoles. Largely divided into three parts, i.e., preclinical anti-cancer effects, clinical anti-cancer effects, and pharmacokinetic properties, we examine the characteristics of each benzimidazole and attempt to elucidate its key properties. Although many studies have demonstrated the anti-cancer effects of benzimidazoles, there is limited evidence regarding their effects in clinical settings. This might be because the clinical trials conducted using benzimidazoles failed to restrict their participants with specific criteria including cancer entities, cancer stages, and genetic characteristics of the participants. In addition, these drugs have limitations including low bioavailability, which results in insufficient plasma concentration levels. Additional studies on whole anti-cancer pathways and development strategies, including formulations, could result significant enhancements of the anti-cancer effects of benzimidazoles in clinical situations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers14194601

Cites

103 of 103 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic diagram of anti-cancer mechanisms of benzimidazoles. (A) Effects of benzimidazoles on cancer cell death, (B) Anti-angiogenic and anti-metastatic effects of benzimidazoles, (C) Inhibitory effects of benzimidazoles on cancer stemness. Abbreviations: Mdm2: mouse double minute 2 homolog; MdmX: mouse double minute 4; RAF: rapidly accelerated fibrosarcoma; MEK: mitogen-activated protein kinase; ERK: extracellular signal-regulated kinases; PI3K: phosphatidylinositol 3-kinase; AKT: protein kinase B; LC3: microtubule-associated protein 1 light chain 3; mTOR: mammalian target of rapamycin; PARP: poly(ADP-ribose) polymerase; Bax: B-cell lymphoma 2 (Bcl-2)-associated X protein; Bcl-2: B-cell lymphoma 2; Bcl-xL: B-cell lymphoma extra-large; VEGF: vascular endothelial growth factor; HIF: hypoxia-inducible factor; STAT3: signal transducer and activator of transcription 3; BCSC: breast cancer stem cell.
Figure 1 Schematic diagram of anti-cancer mechanisms of benzimidazoles. (A) Effects of benzimidazoles on cancer cell death, (B) Anti-angiogenic and anti-metastatic effects of benzimidazoles, (C) Inhibitory effects of benzimidazoles on cancer stemness. Abbreviations: Mdm2: mouse double minute 2 homolog; MdmX: mouse double minute 4; RAF: rapidly accelerated fibrosarcoma; MEK: mitogen-activated protein kinase; ERK: extracellular signal-regulated kinases; PI3K: phosphatidylinositol 3-kinase; AKT: protein kinase B; LC3: microtubule-associated protein 1 light chain 3; mTOR: mammalian target of rapamycin; PARP: poly(ADP-ribose) polymerase; Bax: B-cell lymphoma 2 (Bcl-2)-associated X protein; Bcl-2: B-cell lymphoma 2; Bcl-xL: B-cell lymphoma extra-large; VEGF: vascular endothelial growth factor; HIF: hypoxia-inducible factor; STAT3: signal transducer and activator of transcription 3; BCSC: breast cancer stem cell.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 104 references

Research works printed but not linked: 1

  1. Kim, E.-Y. (2021, December 01). Dog Dewormer Goes Out of Stock Amid Rumor of Efficacy for Cancer. Korea Biomedical Review, 27 December 2019. Available online: https://www.koreabiomed.com/news/articleView.html?idxno=7073.

Cited by

See all 55

Metadata

Authors
Song, B., Park, E. Y., Kim, K. J., & Ki, S. H.
Affiliations
  • Chosun University (KR)
  • Mokpo National University (KR)
Corresponding author
  • Kim, Kwang Joon
  • Ki, Sung Hwan
Venue
Cancers
Publisher
MDPI AG
Published
2022-09-22
Volume
14
Issue
19
Pages
4601
ISSN
2072-6694 (ISSN-L)
OpenAlex
W4296992992
Cited by
55
References
104
Citations by year
2026: 14 · 2025: 13 · 2024: 16 · 2023: 12
FWCI
0.95
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Chosun University
Topics
  • Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
Keywords
benzimidazole anthelmintics, drug repurposing, anticancer activity, pharmacokinetics, bioavailability, clinical trials, drug formulation, antiparasitic drugs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Repurposing of Benzimidazole Anthelmintic Drugs as Cancer Therapeutics. https://app.cochat.ai/papers/10.3390/cancers14194601
The paper
Song, B., Park, E. Y., Kim, K. J., & Ki, S. H. (2022). Repurposing of Benzimidazole Anthelmintic Drugs as Cancer Therapeutics. Cancers. https://doi.org/10.3390/cancers14194601

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.